



EOS imaging obtains regulatory authorization to sell its products in Taiwan

*EOS® can now be deployed in Taiwan,
further advancing the Company's expansion into the Asia-Pacific region*

Paris, 14 April 2014 – EOS imaging (Euronext, FR0011191766-EOSI), the pioneer in orthopaedic 2D/3D imaging, eligible for PEA-PME, today announced that Taiwanese regulatory authorities have authorized the sale of the EOS® imaging system. The EOS imaging system offers ultra-low radiation dose 2D and 3D X-ray imaging of the full body in a natural weight-bearing position. It has already been approved for sale in more than 30 countries.

Approval from Taiwanese regulators represents an important milestone as the Company continues its commercial development efforts in the Asia-Pacific region. EOS has also signed a distribution agreement with the Taiwanese company Unison Co. Ltd. to sell EOS imaging systems in the country.

Marie Meynadier, CEO of EOS imaging, noted: *“the regulatory authorization to deploy our system in Taiwan reflects the continued momentum of our commercial development in the Asia-Pacific region. Together with a strong partnership with our local distributor in Taiwan, this new step now allows us to deploy EOS in this significant Asian market.”*

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 1st half of 2014, on July 22, 2014 (after market).

EOSI
LISTED
NYSE
EURONEXT

Contacts:

Anne Renevot
CFO
Ph: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)
Press relations / Melanie Sollid-Penton
Ph: 646-536-7023
msollid@theruthgroup.com